This analysis looked at which health factors may help predict outcomes for patients with chronic lymphocytic leukemia treated with zanubrutinib, using data from two large studies. Traditionally, patients with TP53 mutations are considered high-risk, have a worse prognosis, and have a shorter time to disease progression – but in this post-hoc analysis, TP53 mutations were not associated with inferior progression-free survival (PFS) in untreated and relapsed/refractory CLL. High levels of lactate dehydrogenase (LDH) were associated with worse outcomes, and only in untreated patients with CLL. New risk-stratification tools may need further investigation to assess risk for patients treated with zanubrutinib in CLL.

The contents of the presentations above are designed for educational and scientific exchange purposes and are not promotional. They may contain information on investigational products or investigational uses of approved products. No conclusions regarding safety and/or efficacy for such investigational products or uses may be made.